Payment overview · 2025
General Payments
$633.75
40 reported records · 11 companies
Healthcare provider profile · identity verified
Christopher Drumm, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORRISTOWN, PA · NPI 1861661415
Verified facts
What the public records show
CMS Open Payments records show Christopher Drumm, M.D. received $633.75 in general payments during 2025 across 40 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.80 | 32.3% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.76 | 25.1% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $66.08 | 10.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.42 | 6.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.39 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.55 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.83 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.05 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.34 | 2.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.06 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.47 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.75 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.66 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.81 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.60 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $66.08 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.28 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 127 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 286 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 71 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
286 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 888 | 243 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 587 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 436 | 114 |
| Losartan Potassium | Losartan Potassium | 351 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 104 |
| Gabapentin | Gabapentin | 336 | 94 |
| Metformin Hcl | Metformin Hcl | 313 | 93 |
| Ozempic | Semaglutide | 286 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 74 |
| Lisinopril | Lisinopril | 274 | 80 |
| Lorazepam | Lorazepam | 261 | 72 |
| Simvastatin | Simvastatin | 251 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 229 | 83 |
| Omeprazole | Omeprazole | 222 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 57 |
| Jardiance | Empagliflozin | 201 | 38 |
| Sertraline Hcl | Sertraline Hcl | 196 | 54 |
| Eliquis | Apixaban | 173 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 46 |
| Carvedilol | Carvedilol | 161 | 53 |
| Furosemide | Furosemide | 160 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 42 |
| Trazodone Hcl | Trazodone Hcl | 154 | 46 |
| Metformin Hcl Er | Metformin Hcl | 151 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 41 |
| Famotidine | Famotidine | 137 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 36 |
| Mounjaro | Tirzepatide | 127 | 20 |
| Allopurinol | Allopurinol | 125 | 36 |
| Meloxicam | Meloxicam | 124 | 53 |
| Glimepiride | Glimepiride | 121 | 32 |
| Synthroid | Levothyroxine Sodium | 118 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 30 |
| Pregabalin | Pregabalin | 112 | 22 |
| Montelukast Sodium | Montelukast Sodium | 106 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 31 |
| Celecoxib | Celecoxib | 96 | 24 |
| Bupropion Xl | Bupropion Hcl | 93 | 20 |
| Spironolactone | Spironolactone | 87 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | 24 |
| Mirtazapine | Mirtazapine | 77 | 20 |
| Donepezil Hcl | Donepezil Hcl | 75 | 20 |
| Valsartan | Valsartan | 74 | 25 |
| Rybelsus | Semaglutide | 71 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 12 |
| Nifedipine Er | Nifedipine | 63 | 18 |
| Prednisone | Prednisone | 62 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 60 | 24 |
| Naproxen | Naproxen | 60 | 24 |
| Finasteride | Finasteride | 59 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 16 |
| Alprazolam | Alprazolam | 52 | 11 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Ibuprofen | Ibuprofen | 50 | 18 |
| Topiramate | Topiramate | 50 | 12 |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Alendronate Sodium | Alendronate Sodium | 47 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 11 |
| Potassium Chloride | Potassium Chloride | 46 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 13 |
| Ezetimibe | Ezetimibe | 42 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 12 |
| Nystatin | Nystatin | 39 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 20 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 12 |
| Atenolol | Atenolol | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 14 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 17 |
| Mometasone Furoate | Mometasone Furoate | 32 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 30 |
| Novolog Flexpen | Insulin Aspart | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 24 |
| Testosterone | Testosterone | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | 12 |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 11 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.75 · 40 records | Novo Nordisk Inc | AIRSUPRA, CAMZYOS, CAPLYTA, Cologuard Collection Kit, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, Symbravo, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error